Generic name: PIBRENTASVIR 40mg, GLECAPREVIR 100mg
Dosage form: tablet, film coated
Medically reviewed on December 14, 2017.
Testing Prior to the Initiation of Therapy
Test all patients for evidence of current or prior HBV infection by measuring hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc) before initiating HCV treatment with MAVYRET [see Warnings and Precautions (5.1)].
Recommended Dosage in Adults
The recommended oral dosage of MAVYRET is three tablets (total daily dose: glecaprevir 300 mg and pibrentasvir 120 mg) taken once daily with food [see Clinical Pharmacology (12.3)].
Tables 1 and 2 provide the recommended MAVYRET treatment duration based on the patient population in HCV mono-infected and HCV/HIV-1 co-infected patients with compensated liver disease (with or without cirrhosis) and with or without renal impairment including patients receiving dialysis.
|No Cirrhosis||Compensated Cirrhosis
|1, 2, 3, 4, 5, or 6||8 weeks||12 weeks|
Treated With a
|1||An NS5A inhibitor1 without prior treatment with an NS3/4A protease inhibitor||16 weeks||16 weeks|
|An NS3/4A PI2 without prior treatment with an NS5A inhibitor||12 weeks||12 weeks|
|1, 2, 4, 5, or 6||PRS3||8 weeks||12 weeks|
|3||PRS3||16 weeks||16 weeks|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Mavyret (glecaprevir / pibrentasvir)
- Mavyret Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 79 Reviews
- Drug class: antiviral combinations